A practical reference on MC4R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-01. Anything still debated is marked as such rather than presented as settled.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
As the organic tin compound, a trimethylstannyl or tributylstannyl compound is normally used. Although trimethylstannyl compounds show higher reactivity compared with tributylstannyl compounds and have much simpler 1H-NMR spectra, the toxicity of the former is much larger. Optimizing which ligands are best at carrying out the reaction with high yield and turnover rate can be difficult. This is because the oxidative addition requires an electron rich metal, hence favoring electron donating ligands. However, an electron deficient metal is more favorable for the transmetalation and reductive elimination steps, making electron withdrawing ligands the best here. Therefore, the optimal ligand set heavily depends on the individual substrates and conditions used. These can change the rate determining step, as well as the mechanism for the transmetalation step. Normally, ligands of intermediate donicity, such as phosphines, are utilized. Rate enhancements can be seen when moderately electron-poor ligands, such as tri-2-furylphosphine or triphenylarsenine are used. Likewise, ligands of high donor number can slow down or inhibit coupling reactions. These observations imply that normally, the rate-determining step for the Stille reaction is transmetalation.
The areas of the Enrichment Center that Chell explores suggest that it is part of a massive research installation. At the time of events depicted in Portal, the facility seems to be long-deserted, although most of its equipment remains operational without human control.
==== GnRH modulators ==== GnRH modulators are antigonadotropins and hence functional antiandrogens. In both males and females, gonadotropin-releasing hormone (GnRH) is produced in the hypothalamus and induces the secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. The gonadotropins signal the gonads to make sex hormones such as testosterone and estradiol. GnRH modulators bind to and inhibit the GnRH receptor, thereby preventing gonadotropin release. As a result of this, GnRH modulators are able to completely shut-down gonadal sex hormone production, and can decrease testosterone levels in men and transgender women by about 95%, or to an equivalent extent as surgical castration. GnRH modulators are also commonly known as GnRH analogues. However, not all clinically used GnRH modulators are analogues of GnRH. There are two types of GnRH modulators: GnRH agonists and GnRH antagonists. These medications have the opposite action on the GnRH receptor but paradoxically have the same therapeutic effects. GnRH agonists, such as leuprorelin (Lupron), goserelin (Zoladex), and buserelin (Suprefact), are GnRH receptor superagonists, and work by producing profound desensitization of the GnRH receptor such that the receptor becomes non-functional. This occurs because GnRH is normally released in pulses, but GnRH agonists are continuously present, and this results in excessive downregulation of the receptor and ultimately a complete loss of function.
Bromley forms part of the Bromley and Biggin Hill Parliament constituency. The current MP is Peter Fortune. Thomas Turrell is the London Assembly member for the Bexley and Bromley constituency, in which the town is located. This post was previously held by Fortune. Bromley's most prominent MP was the former Conservative prime minister, Harold Macmillan. Bromley is part of the Bromley Town ward for elections to Bromley London Borough Council.
=== Catabolism === Isoleucine is both a glucogenic and a ketogenic amino acid. After transamination with alpha-ketoglutarate, the carbon skeleton is oxidised and split into propionyl-CoA and acetyl-CoA. Propionyl-CoA is converted into succinyl-CoA, a TCA cycle intermediate which can be converted into oxaloacetate for gluconeogenesis (hence glucogenic). In mammals acetyl-CoA cannot be converted to carbohydrate but can be either fed into the TCA cycle by condensing with oxaloacetate to form citrate or used in the synthesis of ketone bodies (hence ketogenic) or fatty acids.
Sources: en.wikipedia.org
== Applications == The nanoDSF technology was used to confirm on-target binding of BI-3231 to HSD17B13 and to elucidate its uncompetitive mode of inhibition with regards to NAD+. NanoDSF was used to compare the thermal stability of a matched set of anti-CD20 antibodies representing a range of variants. The results revealed a spectrum of activities. NanoDSF has also been applied in drug repurposing and anticancer research. In a large-scale screen of FDA-approved molecules, the method was used to identify several dozen novel microtubule-targeting agents (MTAs), including clinically used drugs such as aprepitant, disulfiram, and toremifene, by directly demonstrating their interaction with tubulin and their effects on microtubule polymerization.
== R == radioisotope - radioisotopic labelling - Raman spectroscopy - random coil - Ras gene - Ras protein - reading frame - receptor (biochemistry) - receptor antagonist - receptor protein-tyrosine kinase - recombinant fusion protein - recombinant interferon-gamma - recombinant protein - recombination - redox - redox reaction - redox system - reflux - replication origin - replicon - repressor - repressor protein - respiration (physiology) - restriction enzyme - retinoblastoma protein - retinoic acid receptor - retinol-binding protein - retroelement - retroviridae protein - retrovirus - Reverse transcriptase - RFLP - rho factor - rhodopsin - ribonucleoprotein - ribose - ribosomal protein - ribosomal protein S6 kinase - ribosome - RNA - RNA virus - RNA-binding protein - RNA-directed DNA polymerase - rod outer segment - rough ER
Tablets offer several advantages over coffee, tea, and other caffeinated beverages, including convenience, known dosage, and avoidance of concomitant intake of sugar or acids. The use of caffeine in this form may increase alertness. These tablets are commonly used by students studying for their exams and by people who work or drive for long hours.
Cocaine, heroin, cannabis, and other such drugs continued to be legally available without prescription as long as they were labeled. It is estimated that sale of patent medicines containing opiates decreased by 33% after labeling was mandated. In 1906 in Britain and in 1908 in Canada "laws requiring disclosure of ingredients and limitation of narcotic content were instituted". The Harrison Narcotics Tax Act of 1914 restricted the manufacture and distribution of opiates, including laudanum, and coca derivatives in the US. This was followed by France's Loi des stupéfiants in 1916, and Britain's Dangerous Drugs Act in 1920. Laudanum was supplied to druggists and physicians in regular and concentrated versions. For example, in 1915, Frank S. Betz Co., a medical supply company in Hammond, Indiana, advertised Tincture of Opium, U.S.P., for $2.90 per lb., Tincture of Opium Camphorated, U.S.P, for 85 cents per lb., and Tincture of Opium Deodorized, for $2.85 per lb. Four versions of opium as a fluid extract were also offered: (1) Opium, Concentrated (assayed) "For making Tincture Opii (Laudanum) U.S.P. Four times the strength of the regular U.S.P." tincture, for $9.35 per pint; (2) Opium, Camphorated Conc. "1 oz. making 8 ozs. Tr. Opii Camphorated U.S.P (Paregoric)" for $2.00 per pint; (3) Opium, Concentrated (Deodorized and Denarcotized) "Four times the strength of tincture, Used when Tinct. Opii U.S.P. is contraindicated" for $9.50 per pint, and (4) Opium (Aqueous), U.S.P., 1890, "Tr. (assayed) Papaver Somniferum" for $2.25 per pint.
Tedizolid, sold under the brand name Sivextro (by Merck) is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)). The most common side effects include nausea (feeling sick), headache, diarrhea and vomiting. These side effects were generally of mild or moderate severity. Tedizolid was approved for medical use in the United States in June 2014, and authorized for medical use in the European Union in March 2015. Tedizolid phosphate is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
Sources: en.wikipedia.org
The journalist and diplomat José Rodríguez Elizondo maintained that from that moment on, a relationship with Peru was consolidated in Chile, inspired by mistrust and prejudice, where the Chileanization carried out by the Patriotic Leagues would be the definitive establishment of mass nationalism, almost Chilean chauvinism, which "led to exalt xenophobic features, fundamentally anti-Peruvian". This perspective, with its nuances, became accessible to many sectors beyond Tarapacá, such as the embarrassing event of Don Ladislao's War, in which accuse of "sold out Peruvian gold" anyone who questioned the action of Minister of War, Ladislao Errázuriz, of mobilizing troops from Santiago to the north, in a farce to attack a fictitious Peruvian enemy, while in reality he wanted the army away from the capital (due to its proximity to the candidate Arturo Alessandri Palma). In addition, innumerable newspapers, starting with the newspapers and magazines of the mainstream press (El Mercurio, El Diario Ilustrado, El Chileno, Zig-Zag and Sucesos), shared a similar idea of the conception of the homeland. In Congress, this thought full of Peruvian-phobic prejudices was personified by the Balmacedista deputy, Anselmo Blanlot, who would end up propagating the idea that the anti-Peruvian violence in the north was truly "imaginary attacks." Peru was seen as barbarism and Chile, it was supposed, light and civilization. Other politicians with anti-Peruvian tendencies were Agustín Edwards Mac-Clure, Víctor Eastman Cox or Rafael Edwards Salas.
=== Conflict wounds === In 2018, the Scar Free Foundation Centre for Conflict Wound Research was established at the Royal Centre for Defence Medicine in Queen Elizabeth Hospital, Birmingham. The centre's studies aim to mitigate the physical and psychological impacts of scarring among servicemen, women, and individuals injured in terrorist attacks. It was established in partnership with the CASEVAC Club, a members organisation similar to the Guinea Pig Club.
Pressed and dried: Vascular plant (flowering plants, conifers, ferns) specimens are pressed and dried plants that are mounted on herbarium sheets. Various techniques are used to attach the plants with the most common method of using archival adhesive with heavier portions of the plant supported additionally by linen thread or narrow strips of gum-backed linen tape or polyester film. Specimens are best pressed with moderate pressure, permitting as much air circulation as possible. This is commonly achieved by strapping sheets in a press made of heavy cardboard or plywood. If there are loose seeds or fruits, these are placed in a small fragment packet, which also is glued to the sheet. A label with collection information is glued on the bottom right corner. Dried: Small bryophytes (mosses, hepatics or liverworts, and hornworts) are dried and placed loosely in folded packets. The label is glued on the front of the packet and the packets are filed loosely in boxes, glued to sheets of mounting paper, or placed loosely in folders. Stored in fluid: Preserved material can be kept in a glass jar filled with preservative fluid. By storing this way, the botanical specimens are maintained in a usable condition by inhibiting enzymatic and microbial attack. This method can be used where drying, pressing and mounting on a herbarium sheet is unsuitable. This method allows for a better three-dimensional arrangement of flower parts or fruits for storage.
=== Person-centred approach === Person-centred clinical management is widely recognised as an effective and sustainable model for chronic disease care. Kalra has extensively applied person-centred principles to insulin initiation and intensification. He has also examined barriers to insulin use, especially in low- and middle-income countries, and suggested frameworks ("bridges") to address these challenges. Kalra has been lead author for several multinational panels and evidence-based recommendations on individualising time-in-range goals, and on administration techniques, including work published in Mayo Clinic Proceedings.
1952: American computer scientist Grace Hopper completed what is considered to be the first compiler, a program that allows a computer user to use a human-readable high-level programming language instead of machine code. It was known as the A-0 compiler. 1952: Photograph 51, an X-ray diffraction image of crystallized DNA, was taken by Raymond Gosling in May 1952, working as a PhD student under the supervision of British chemist and biophysicist Rosalind Franklin; it was critical evidence in identifying the structure of DNA. 1952: Canadian agriculturalist Mary MacArthur became the first female Fellow of the Agricultural Institute of Canada for her contributions to the science of food dehydration and freezing. 1952: American physician, obstetrical anesthesiologist and medical researcher Virginia Apgar devised the Apgar score, a way to quickly assess the health of a new-born child immediately after birth in order to combat infant mortality. 1953: Canadian-British radiobiologist Alma Howard co-authored a paper proposing that cellular life transitions through four distinct periods. This became the first concept of the cell cycle. 1954: New Zealand botanist Lucy Cranwell was the first female recipient of the Hector Medal from the Royal Society of New Zealand. She was recognized for her pioneering work with pollen in the emerging field of palynology. 1955: Scottish-Canadian Arctic ice researcher Moira Dunbar became the first female glaciologist to study sea ice from a Canadian icebreaker ship.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.